

## **GRADUATE CERTIFICATE IN HEALTH PRODUCTS REGULATION GMS5116 POST-MARKET ACTIVITIES FOR PHARMACEUTICALS**

25 September – 29 September 2023

---

### **Overall objectives of the workshop**

- Build and enhance capability for the key activities and roles essential for effective post-market control of pharmaceutical products.
- Promote opportunities for optimisation of post-market surveillance networks and collaboration, handling of substandard and falsified pharmaceuticals within ASEAN region.

### **Learning outcomes**

- Describe the post-market surveillance and enforcement activities to monitor and ensure the quality and safety of pharmaceutical products
- Explain the role of good manufacturing practices (GMP) and good storage and distribution practices (GSDP) in safeguarding the quality of approved pharmaceutical products across the product lifecycle
- List the national and international platforms and initiatives that are supporting post-market regulatory activities to enhance supply chain integrity of pharmaceutical products and facilitate timely interventions

**Copyright statement**

This material is the property of the Duke-NUS Medical School. It is not to be duplicated or distributed without written permission of the Executive Director and the management team of the Centre of Regulatory Excellence of Duke-NUS Medical School.

# Graduate Certificate in Health Products Regulation

## GMS5116 Post-Market Activities for Pharmaceuticals

**25 - 29 September 2023**

**Day 1 – September 25, Mon**

Time	Agenda	Faculty
8.30 am	Welcome and workshop briefing	<b>Dr. Rathi Saravanan</b> Lead Education Associate Centre of Regulatory Excellence (CoRE) Duke-NUS Medical School
9.00 am	Group activity/ Bright Space and Assessment Familiarisation	<b>Mr Osman Mohamad</b> Senior Associate CoRE, Duke-NUS Medical School
<b>Session 1: Post-Market Surveillance Overview &amp; Supporting Best Practices and Systems</b>		
9.30 am	<b>Post-market surveillance programme: Role in ensuring pharmaceutical product quality across supply chain</b> <ul style="list-style-type: none"> <li>Objectives and stakeholder responsibilities</li> <li>Applicable General principles (e.g.GMP and GSDP)</li> <li>Sampling and quality control testing</li> </ul>	<b>Asst Prof James Leong</b> Head, Health Products and Regulatory Science CoRE, Duke-NUS Medical School
<b>10.00 am Break</b>		
10:15 am	<b>Quality Management System (QMS) in ensuring pharmaceutical product quality and reliability of supply chain.</b> <ul style="list-style-type: none"> <li>QMS Elements</li> <li>QMS Regulations and standards (ISO 9001:2015/ICH Q10)</li> <li>Role of QMS in achieving quality compliance across supply chain</li> </ul>	<b>Ms. Teo Jing Yi</b> CMC Regulatory MSD International GmbH
11:15 am	<b>Quality Risk Management (QRM) as part of supply chain integrity and control</b> <ul style="list-style-type: none"> <li>QRM principles (ICH Q9 (R1))</li> <li>QRM methodology</li> <li>Role of QRM in achieving quality compliance across supply chain</li> </ul>	<b>Ms. Teo Jing Yi</b> CMC Regulatory MSD International GmbH
<b>12.30pm Lunch</b>		
<b>Session 2: Ensuring pharmaceutical product quality across supply chain - GMP</b>		
1.30 pm	<b>Role of Good Manufacturing Practices (GMP) in quality assurance of pharmaceutical products across supply chain</b> <ul style="list-style-type: none"> <li>Basic Principles of GMP</li> <li>GMP requirements for quality control</li> </ul>	<b>Mr Vimal Sachdeva</b> Technical Officer – Senior Inspector Inspection Services Group Prequalification Team (PQT) World Health Organization (WHO)
2.15 pm	<b>Types of GMP inspections and classification of deficiencies</b> <ul style="list-style-type: none"> <li>Risk-based categorization of deficiencies</li> <li>Specific product deficiencies (e.g., Biologics, CTGTPs)</li> <li>Communication of Inspection Report</li> </ul>	<b>Mr Vimal Sachdeva</b> WHO
<b>3.00 pm Break</b>		

3.15 pm	<b>Being GMP Compliant: Operational considerations, planning and preparation for post-approval inspections</b> <ul style="list-style-type: none"> <li>• Proactive compliance &amp; Inspection readiness</li> <li>• Approaches and systems supporting inspections</li> <li>• Roles and responsibility of management</li> </ul>	<b>Dr. Stephen Hsu</b> Regional Head Quality Assurance Alcon, Singapore
4.30 pm	<b>Co-operation and mutual reliance in GMP Inspections</b> <ul style="list-style-type: none"> <li>• Global supply chain complexities &amp; importance of inspection reliance in quality compliance and assurance</li> <li>• PIC/S inspection reliance initiatives</li> <li>• ASEAN MRA on GMP inspections</li> </ul>	<b>Mr. Boon Meow Hoe</b> Deputy Director Senior GMP Auditor Audit & Licensing Division Health Products Regulation Group Health Sciences Authority (HSA) Singapore
5.30 pm	<b>End</b>	

## Day 2 – September 26, Tue

Time	Agenda	Faculty
8.30 am	Individual and Group Assessment I	<b>CoRE Education team</b>
<b>Session 3: Ensuring pharmaceutical product quality across supply chain – GSDP</b>		
9.30 am	<b>Overview of Good Storage Distribution Practice in supply chain integrity of medicinal products</b> <ul style="list-style-type: none"> <li>• Importance of GSDP</li> <li>• Best practices and principles on GSDP</li> </ul>	<b>Mr. Brett Marshall</b> Vice President – Quality & HSSE Zuellig Pharma Holdings Pte Ltd
<b>10.00 am</b>	<b>Break</b>	
10.15 am	<b>Maintaining a secure pharmaceutical supply chain</b> <ul style="list-style-type: none"> <li>• Threats and Challenges</li> <li>• Supply chain security measures</li> <li>• Handling of supply chain security breaches</li> <li>• Detection technologies with focus on suspected substandard and falsified pharmaceutical products</li> </ul>	<b>Mr. Brett Marshall</b> Zuellig Pharma
11.00 am	<b>Ensuring quality and integrity of vaccines across supply chain</b> <ul style="list-style-type: none"> <li>• Freezing threat and cold chain management</li> <li>• Tools and approaches for temperature monitoring</li> <li>• Enhanced Safety monitoring measures</li> </ul>	<b>Mr. Brett Marshall</b> Zuellig Pharma
11.30 am	<b>Good Storage and Distribution Practices for ATMPs</b> <ul style="list-style-type: none"> <li>• Needs and Challenges in Cell &amp; Gene therapy Supply Chain</li> <li>• Supporting operations &amp; infrastructure</li> <li>• Best practices ensuring supply chain integrity</li> </ul>	<b>Ms. Cathleen E. Afable</b> CQA, CMQ/OE (ASQ) Regional Director, International Markets Cell Therapy Operations, Novartis Singapore
<b>12.00 noon Lunch</b>		
1.00 pm	<b>Case Discussion I: CAPA</b>	<b>Asst Prof James Leong</b> CoRE
<b>3.00 pm</b>	<b>Break</b>	
3.15 pm	<b>Practicum I: GMP</b>	<b>Content Expert</b> <b>Mr Vimal Sachdeva</b> WHO
<b>5.30 pm</b>	<b>End</b>	

## Day 3 – September 27, Wed

Time	Agenda	Faculty
8.30am	Individual and Group Assessment II	<b>CoRE Education team</b>
9.30 am	Peer Learning and Sharing	<b>CoRE Education team</b>
<b>10. 00 am</b>	<b>Break</b>	
<b>Session 4: Ensuring pharmaceutical product quality and supply chain security- Post-market surveillance activities for approved medicinal products</b>		
10.15 am	<b>Pharmaceutical quality surveillance in Singapore</b> <ul style="list-style-type: none"> <li>• Purposes</li> <li>• Sampling criteria</li> <li>• Laboratory testing</li> </ul>	<b>Ms Yang Silin</b> Senior Regulatory Specialist Vigilance and Compliance Branch Health Products Regulation Group HSA, Singapore
11.30 am	<b>Reporting of therapeutic product defects and recall</b> <ul style="list-style-type: none"> <li>• Classification of product quality defects</li> <li>• Level of recalls</li> <li>• Investigation, corrective and preventive actions</li> </ul>	<b>Mr Choong Chih Tzer</b> Senior Regulatory Specialist HSA, Singapore
<b>12.30 noon</b>	<b>Lunch</b>	
1.30 pm	<b>Practicum II: Management of pharmaceutical product quality surveillance for out-of-specifications (OOS) and product quality defects</b>	<u><b>Content Experts</b></u> <b>Ms Yang Silin</b> HSA, Singapore  <b>Mr Choong Chih Tzer</b> HSA, Singapore
<b>3.30 pm</b>	<b>Break</b>	
3.45 pm	<b>Practicum II: Discussion</b>	
4.30 pm	<b>Risk-Based Post-Market Product Quality Surveillance</b> <ul style="list-style-type: none"> <li>• Considerations for effective post-market surveillance</li> <li>• Guidance for establishing and implementing risk-based surveillance tool</li> </ul>	<b>Ms Ruth Lee</b> Associate Director Public Policy and Regulatory Affairs Global External Affairs, APAC United States Pharmacopeial Convention (USP)
<b>5.30pm</b>	<b>End</b>	

## Day 4 – September 28, Thurs

Time	Agenda	Faculty
8.30am	Individual and Group Assessment III	<b>CoRE Education team</b>
<b>Session 5: Ensuring pharmaceutical product quality and supply chain security – Surveillance activities for Counterfeit, Substandard and Falsified medicinal products</b>		
9.30 am	<p><b>Trend Observation on Counterfeits (CF), Substandard and Falsified (SF) Medicines in the Asia-Pacific Region</b></p> <ul style="list-style-type: none"> <li>• What are CF and SF medicines</li> <li>• Hot spot areas in the Asia-Pacific region and the contributory factors</li> <li>• Impact of CF and SF medicines to public health</li> </ul>	<p><b>Mr Ramesh Raj Kishore</b> Regional Director – Asia Pacific Pharmaceutical Security Institute Singapore</p>
<b>10.15 am</b>	<b>Break</b>	
10.30 am	<b>Practicum III: Detection of SF medicinal product</b>	<p><b>Content Expert</b> <b>Mr Ramesh Raj Kishore</b> Pharmaceutical Security Institute Singapore</p>
<b>12.30 pm Lunch</b>		
<b>Session 6: Ensuring pharmaceutical product quality and supply chain security – Enforcement activities</b>		
1.30 pm	<p><b>Enforcement efforts against SF and illegal sales of medicinal products in ASEAN</b></p> <ul style="list-style-type: none"> <li>• Magnitude of issue in ASEAN landscape</li> <li>• Types of operations carried out</li> <li>• Collaboration with other agencies intra- and inter-countries</li> </ul>	<p><b>Mr. Jonathan Selvasegaram</b> Asia Pacific Manager and Legal Counsel React</p>
2. 30 pm	<p><b>Global enforcement efforts against SF and illegal sales of medicinal products</b></p> <ul style="list-style-type: none"> <li>• Magnitude of issues worldwide</li> <li>• Strategies to combat existing and emerging global threat</li> </ul>	<p><b>Ms Ruth Lee</b> USP</p>
<b>3.30 pm</b>	<b>Break</b>	
3.45 pm	<b>Case discussion II: Enforcement operations against SF medicines</b>	<b>CoRE Education team</b>
5.15 pm	<b>Group Activity – Preparation for panel discussion/ EOM preparation</b>	<b>CoRE Education team</b>
<b>5.30pm</b>	<b>End</b>	

## Day 5 – September 29, Fri

Time	Agenda	Faculty
9.00am	End-of-Module (EOM) assessment	CoRE Education team
10.00 am	Discussion for EOM	CoRE Education team
<b>10.30 am</b>	<b>Break</b>	
<b>Session 7: Emerging Technologies in Pharmaceutical supply chain management and Regulatory Systems strengthening</b>		
10.45 am	<b>Regulatory Systems Strengthening to mitigate issues of Substandard and Falsified medicines</b>	<b>Dr. Valerio Reggi</b> Visiting Expert, CoRE Consultant, Drug Regulatory Matters & Pharmaceutical Policy
11.45 am	<b>Block chain enabled end-to-end traceability and supply chain resilience</b>	<b>Associate Prof. Sunil Tiwari</b> ESSCA School of Management France
<b>12.30 pm</b>	<b>Lunch</b>	
1.30 pm	<b>Capacity building for resilient vaccine supply chains</b> <ul style="list-style-type: none"> <li>Global and LMIC Case examples</li> </ul>	<b>Mr. Brett Marshall</b> Zuellig Pharma
2.30 pm	<b>Regulatory systems strengthening for supply chain integrity and security</b>	<b>Ms Ruth Lee</b> USP
3.30 pm	<b><u>Panel discussion</u></b> <b>Facilitating a regional approach to combatting substandard and falsified medicines and impact on access and global health</b>	<b><u>Panellist</u></b> <b>Ms Ruth Lee</b> USP  <b>Mr. Brett Marshall,</b> Zuellig Pharma  <b><u>Moderator</u></b> <b>Mr Ramesh Raj</b> Pharmaceutical Security Institute
4.45 pm	<b>Workshop conclusion</b>	<b>A/Prof Silke Vogel</b> Senior Associate Dean, Graduate Studies Deputy Director, CoRE Head, Centre for Lifelong Learning Duke-NUS Medical School
4.50 pm	<b>High-Tea and Networking Session</b>	<b>Faculty, Participants and CoRE Members</b>
<b>5.30 pm</b>	<b>End</b>	